Skip to content

Effects of sleep-disordered breathing (SDB) on behavior, cognition and maxilloficial development of children

Effects of sleep-disordered breathing (SDB) on behavior, cognition and maxilloficial development of children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026807
Enrollment
Unknown
Registered
2019-10-23
Start date
2019-12-02
Completion date
Unknown
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep-disordered breathing of children

Interventions

mild-OSA, moderate-OSA, sereve-OSA, PS group:Without any Measure

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 16 Years

Inclusion criteria

Inclusion criteria: (1) the outpatients complained of "open mouth breathing" and "habitual snoring" to the outpatients of our hospital; (2) children and adolescents aged 3-16 years; (3) children and adolescents whose guardians signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) craniofacial abnormalities, including cleft lip and palate or submucous cleft palate, or any anatomical or general condition that hinders general anesthesia or standard removal of tonsil and adenoid tissue; (2) serious health problems, which can be exacerbated by delayed treatment of OSA, including: serious cardiopulmonary diseases (such as cystic fibrosis, congenital heart disease); sickle S-cell disease; poorly controlled asthma (more than one hospitalization last year); epilepsy requiring drug treatment; diabetes mellitus (type 1 or 2) requiring drug treatment; diagnosed heart disease or cor pulmonale; stage II hypertension (HTN) with a history percentage greater than 99% and / or requiring drug treatment; mental retardation; chronic special infection (such as HIV). (3) the guardian or the child requires to withdraw from the study or has poor compliance; (4) during the follow-up period of 1 year before or after treatment (conservative, surgical, drug), mental or behavioral disorders that need or may need to start new drugs, treatment or other special treatment; (5) confirmed genetic, craniofacial, neurological or mental system diseases; (6) current use: ADHD Drugs, psychotropic drugs, hypnotics, hypoglycemic drugs or insulin, antihypertensive drugs, growth hormone, anticonvulsant drugs, anticoagulants, daily oral corticosteroids; (7) participants who were not considered suitable by the researchers.

Design outcomes

Primary

MeasureTime frame
OSA-18 scale;PSG;CBCL scale for children;Lateral radiograph of skull base;

Secondary

MeasureTime frame
Height, weight, blood pressure, etc.;

Countries

China

Contacts

Public ContactZou Jian

West China Hospital, Sichuan University

65874911@qq.com+86 18980605883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026